These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies. Nabar N; Dacoba TG; Covarrubias G; Romero-Cruz D; Hammond PT Proc Natl Acad Sci U S A; 2024 Mar; 121(11):e2307809121. PubMed ID: 38437543 [TBL] [Abstract][Full Text] [Related]
6. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing. Qiu M; Li Y; Bloomer H; Xu Q Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716 [TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy. Soroudi S; Jaafari MR; Arabi L J Control Release; 2024 Aug; 372():113-140. PubMed ID: 38876358 [TBL] [Abstract][Full Text] [Related]
8. Chemistry of Lipid Nanoparticles for RNA Delivery. Eygeris Y; Gupta M; Kim J; Sahay G Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635 [TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311 [TBL] [Abstract][Full Text] [Related]
10. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size. Shi R; Liu X; Wang Y; Pan M; Wang S; Shi L; Ni B Hum Vaccin Immunother; 2024 Dec; 20(1):2342592. PubMed ID: 38714327 [TBL] [Abstract][Full Text] [Related]
11. An Ionizable Lipid Material with a Vitamin E Scaffold as an mRNA Vaccine Platform for Efficient Cytotoxic T Cell Responses. Oyama R; Ishigame H; Tanaka H; Tateshita N; Itazawa M; Imai R; Nishiumi N; Kishikawa JI; Kato T; Anindita J; Nishikawa Y; Maeki M; Tokeshi M; Tange K; Nakai Y; Sakurai Y; Okada T; Akita H ACS Nano; 2023 Oct; 17(19):18758-18774. PubMed ID: 37814788 [TBL] [Abstract][Full Text] [Related]
12. Design of PD-L1-Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy. Kim Y; Choi J; Kim EH; Park W; Jang H; Jang Y; Chi SG; Kweon DH; Lee K; Kim SH; Yang Y Adv Sci (Weinh); 2024 Jun; 11(22):e2309917. PubMed ID: 38520717 [TBL] [Abstract][Full Text] [Related]
13. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174 [TBL] [Abstract][Full Text] [Related]
14. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Pardi N; Tuyishime S; Muramatsu H; Kariko K; Mui BL; Tam YK; Madden TD; Hope MJ; Weissman D J Control Release; 2015 Nov; 217():345-51. PubMed ID: 26264835 [TBL] [Abstract][Full Text] [Related]
15. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells. Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637 [TBL] [Abstract][Full Text] [Related]
16. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab. Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398 [TBL] [Abstract][Full Text] [Related]
17. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines. Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150 [TBL] [Abstract][Full Text] [Related]
18. pH-Responsive β-Glucans-Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy. Luo PK; Ho HM; Chiang MC; Chu LA; Chuang YH; Lyu PC; Hu IC; Chang WA; Peng SY; Jayakumar J; Chen HL; Huang MH; Sung HW Adv Mater; 2024 Aug; 36(33):e2404830. PubMed ID: 38895941 [TBL] [Abstract][Full Text] [Related]
19. Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery. Sun M; Dang UJ; Yuan Y; Psaras AM; Osipitan O; Brooks TA; Lu F; Di Pasqua AJ AAPS PharmSciTech; 2022 May; 23(5):135. PubMed ID: 35534697 [TBL] [Abstract][Full Text] [Related]
20. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection. Takanashi A; Pouton CW; Al-Wassiti H Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]